Search This Blog

Tuesday, March 3, 2026

Moderna to pay $950 m upfront, up to $1.3 b more to Arbutus and Genevant in COVID patent settlement

 


  • Settlement ends COVID-19 vaccine patent litigation, eliminates future royalties and clears a key overhang on Moderna’s mRNA pipeline.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)